-
1
-
-
14944383798
-
The evolving role of natural products in drug discovery
-
[1] Koehn, F.E., Carter, G.T., The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4 (2005), 206–220.
-
(2005)
Nat. Rev. Drug Discov.
, vol.4
, pp. 206-220
-
-
Koehn, F.E.1
Carter, G.T.2
-
2
-
-
84926205808
-
The re-emergence of natural products for drug discovery in the genomics era
-
[2] Harvey, A.L., Edrada-Ebel, R., Quinn, R.J., The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 14 (2015), 111–129.
-
(2015)
Nat. Rev. Drug Discov.
, vol.14
, pp. 111-129
-
-
Harvey, A.L.1
Edrada-Ebel, R.2
Quinn, R.J.3
-
3
-
-
84964698735
-
Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents
-
[3] Chen, H., Gao, Y., Wang, A., Zhou, X., Zheng, Y., Zhou, J., Evolution in medicinal chemistry of ursolic acid derivatives as anticancer agents. Eur. J. Med. Chem. 92 (2015), 648–655.
-
(2015)
Eur. J. Med. Chem.
, vol.92
, pp. 648-655
-
-
Chen, H.1
Gao, Y.2
Wang, A.3
Zhou, X.4
Zheng, Y.5
Zhou, J.6
-
4
-
-
84910006077
-
Exploring therapeutic potentials of baicalin and its aglycone baicalin for hematological malignancies
-
[4] Chen, H., Gao, Y., Wu, J., Chen, Y., Chen, B., Hu, J., Zhou, J., Exploring therapeutic potentials of baicalin and its aglycone baicalin for hematological malignancies. Cancer Lett. 354 (2014), 5–11.
-
(2014)
Cancer Lett.
, vol.354
, pp. 5-11
-
-
Chen, H.1
Gao, Y.2
Wu, J.3
Chen, Y.4
Chen, B.5
Hu, J.6
Zhou, J.7
-
5
-
-
84962367258
-
Natural products as sources of new drugs from 1981 to 2014
-
PMID: 26718746
-
[5] Newman, D.J., Cragg, G.M., Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod., 2016, 10.1021/acs.jnatprod.5b01055 PMID: 26718746.
-
(2016)
J. Nat. Prod.
-
-
Newman, D.J.1
Cragg, G.M.2
-
6
-
-
84905495729
-
The discovery of first-in-class drugs: origins and evolution
-
[6] Eder, J., Sedrani, R., Wiesmann, C., The discovery of first-in-class drugs: origins and evolution. Nat. Rev. Drug Discov. 13 (2014), 577–587.
-
(2014)
Nat. Rev. Drug Discov.
, vol.13
, pp. 577-587
-
-
Eder, J.1
Sedrani, R.2
Wiesmann, C.3
-
7
-
-
80052937334
-
Artemisinin: discovery from the Chinese herbal garden
-
[7] Miller, L.H., Su, X., Artemisinin: discovery from the Chinese herbal garden. Cell 146 (2011), 855–858.
-
(2011)
Cell
, vol.146
, pp. 855-858
-
-
Miller, L.H.1
Su, X.2
-
8
-
-
84944174789
-
Anti-parasite drugs sweep Nobel prize in medicine 2015
-
[8] Callaway, E., Cyranoski, D., Anti-parasite drugs sweep Nobel prize in medicine 2015. Nature 526 (2015), 174–175.
-
(2015)
Nature
, vol.526
, pp. 174-175
-
-
Callaway, E.1
Cyranoski, D.2
-
9
-
-
84868685907
-
Terpenoids: natural products for cancer therapy
-
[9] Huang, M., Lu, J.J., Huang, M.Q., Bao, J.L., Chen, X.P., Wang, Y.T., Terpenoids: natural products for cancer therapy. Expert Opin. Investig. Drugs 21 (2012), 1801–1818.
-
(2012)
Expert Opin. Investig. Drugs
, vol.21
, pp. 1801-1818
-
-
Huang, M.1
Lu, J.J.2
Huang, M.Q.3
Bao, J.L.4
Chen, X.P.5
Wang, Y.T.6
-
10
-
-
76849087811
-
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer
-
[10] Bedard, P.L., Di, L.A., Piccart-Gebhart, M.J., Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat. Rev. Clin. Oncol. 7 (2010), 22–36.
-
(2010)
Nat. Rev. Clin. Oncol.
, vol.7
, pp. 22-36
-
-
Bedard, P.L.1
Di, L.A.2
Piccart-Gebhart, M.J.3
-
11
-
-
49949133123
-
Diterpenoid constituents of Isodon trichocarpus and Isodon japonicus (terpenoids IV)
-
[11] Fujita, E., Fujita, T., Shibuya, M., Diterpenoid constituents of Isodon trichocarpus and Isodon japonicus (terpenoids IV). Tetrahedron Lett. 7 (1966), 3153–3162.
-
(1966)
Tetrahedron Lett.
, vol.7
, pp. 3153-3162
-
-
Fujita, E.1
Fujita, T.2
Shibuya, M.3
-
12
-
-
4243522003
-
Oridonin, a new diterpenoid from Isodon species
-
[12] Fujita, E., Fujita, T., Katayama, H., Shibuya, M., Oridonin, a new diterpenoid from Isodon species. Chem. Commun., 1967, 252–254.
-
(1967)
Chem. Commun.
, pp. 252-254
-
-
Fujita, E.1
Fujita, T.2
Katayama, H.3
Shibuya, M.4
-
13
-
-
0017172723
-
The antitumor and antibacterial activity of the Isodon diterpenoids
-
[13] Fujita, E., Nagao, Y., Kaneko, K., Nakazawa, S., Kuroda, H., The antitumor and antibacterial activity of the Isodon diterpenoids. Chem. Pharm. Bull. 24 (1976), 2118–2127.
-
(1976)
Chem. Pharm. Bull.
, vol.24
, pp. 2118-2127
-
-
Fujita, E.1
Nagao, Y.2
Kaneko, K.3
Nakazawa, S.4
Kuroda, H.5
-
14
-
-
85043181998
-
-
L-alanine-(14-oridonin) ester trifluoroacetate as well as preparation method and application, Chinese Patent (2014) CN 104017000 A.
-
[14] P.Y. Sun, G.L. Wu, Z.J. Qiu, Y.J. Chen, L-alanine-(14-oridonin) ester trifluoroacetate as well as preparation method and application, Chinese Patent (2014) CN 104017000 A.
-
-
-
Sun, P.Y.1
Wu, G.L.2
Qiu, Z.J.3
Chen, Y.J.4
-
15
-
-
79960555687
-
Anti-cancer natural products isolated from Chinese medicinal herbs
-
[15] Tan, W., Lu, J., Huang, M., Li, Y., Chen, M., Wu, G., Gong, J., Zhong, Z., Xu, Z., Dang, Y., Guo, J., Chen, X., Wang, Y., Anti-cancer natural products isolated from Chinese medicinal herbs. Chin. Med., 6, 2011, 27.
-
(2011)
Chin. Med.
, vol.6
, pp. 27
-
-
Tan, W.1
Lu, J.2
Huang, M.3
Li, Y.4
Chen, M.5
Wu, G.6
Gong, J.7
Zhong, Z.8
Xu, Z.9
Dang, Y.10
Guo, J.11
Chen, X.12
Wang, Y.13
-
16
-
-
70350624803
-
Efficacy of Rabdosia rubescens in the treatment of gingivitis
-
[16] Chen, S., Liu, J., Zhang, H., Efficacy of Rabdosia rubescens in the treatment of gingivitis. J. Huazhong Univ. Sci. Technol. Med. Sci. 29 (2009), 659–663.
-
(2009)
J. Huazhong Univ. Sci. Technol. Med. Sci.
, vol.29
, pp. 659-663
-
-
Chen, S.1
Liu, J.2
Zhang, H.3
-
17
-
-
79952914222
-
Therapeutic effect of Rabdosia rubescens aqueous extract on chronic pharyngitis and its safety
-
[17] Ma, Z., Hu, C., Zhang, Y., Therapeutic effect of Rabdosia rubescens aqueous extract on chronic pharyngitis and its safety. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 36 (2011), 170–173.
-
(2011)
Zhong Nan Da Xue Xue Bao Yi Xue Ban.
, vol.36
, pp. 170-173
-
-
Ma, Z.1
Hu, C.2
Zhang, Y.3
-
18
-
-
21644460399
-
Rabdosia rubescens inhibits breast cancer growth and angiogenesis
-
[18] Sartippour, M.R., Seeram, N.P., Heber, D., Hardy, M., Norris, A., Lu, Q., Zhang, L., Lu, M., Rao, J.Y., Brooks, M.N., Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int. J. Oncol. 26 (2005), 121–127.
-
(2005)
Int. J. Oncol.
, vol.26
, pp. 121-127
-
-
Sartippour, M.R.1
Seeram, N.P.2
Heber, D.3
Hardy, M.4
Norris, A.5
Lu, Q.6
Zhang, L.7
Lu, M.8
Rao, J.Y.9
Brooks, M.N.10
-
19
-
-
47849123320
-
Inflammatory aortitis controlled by the Chinese herbal remedy Donglingcao Pian
-
[19] De Silva, C., Stevens, R., Jordan, K.M., Inflammatory aortitis controlled by the Chinese herbal remedy Donglingcao Pian. Rheumatology 47 (2008), 1257–1259.
-
(2008)
Rheumatology
, vol.47
, pp. 1257-1259
-
-
De Silva, C.1
Stevens, R.2
Jordan, K.M.3
-
20
-
-
1642540641
-
Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells
-
[20] Ikezoe, T., Chen, S.S., Tong, X.J., Heber, D., Taguchi, H., Koeffler, H.P., Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int. J. Oncol. 23 (2003), 1187–1193.
-
(2003)
Int. J. Oncol.
, vol.23
, pp. 1187-1193
-
-
Ikezoe, T.1
Chen, S.S.2
Tong, X.J.3
Heber, D.4
Taguchi, H.5
Koeffler, H.P.6
-
21
-
-
23044504665
-
Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens
-
[21] Leung, C.H., Grill, S.P., Lam, W., Han, Q.B., Sun, H.D., Cheng, Y.C., Novel mechanism of inhibition of nuclear factor-kappa B DNA-binding activity by diterpenoids isolated from Isodon rubescens. Mol. Pharmacol. 68 (2005), 286–297.
-
(2005)
Mol. Pharmacol.
, vol.68
, pp. 286-297
-
-
Leung, C.H.1
Grill, S.P.2
Lam, W.3
Han, Q.B.4
Sun, H.D.5
Cheng, Y.C.6
-
22
-
-
25844511169
-
Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the Chinese herb Rabdosia rubescens
-
[22] Hsieh, T.C., Wijeratne, E.K., Liang, J.Y., Gunatilaka, A.L., Wu, J.M., Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the Chinese herb Rabdosia rubescens. Biochem. Biophys. Res. Commun. 337 (2005), 224–231.
-
(2005)
Biochem. Biophys. Res. Commun.
, vol.337
, pp. 224-231
-
-
Hsieh, T.C.1
Wijeratne, E.K.2
Liang, J.Y.3
Gunatilaka, A.L.4
Wu, J.M.5
-
23
-
-
84925880439
-
Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies
-
[23] Zhao, Z., Chen, Y., Oridonin, a promising antitumor natural product in the chemotherapy of hematological malignancies. Curr. Pharm. Biotechnol. 15 (2014), 1083–1092.
-
(2014)
Curr. Pharm. Biotechnol.
, vol.15
, pp. 1083-1092
-
-
Zhao, Z.1
Chen, Y.2
-
24
-
-
84885574287
-
Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin
-
[24] Tian, W., Chen, S.Y., Recent advances in the molecular basis of anti-neoplastic mechanisms of oridonin. Chin. J. Integr. Med. 19 (2013), 315–320.
-
(2013)
Chin. J. Integr. Med.
, vol.19
, pp. 315-320
-
-
Tian, W.1
Chen, S.Y.2
-
25
-
-
84868142361
-
Oridonin: targeting programmed cell death pathways as an anti-tumour agent
-
[25] Liu, Z., Ouyang, L., Peng, H., Zhang, W.Z., Oridonin: targeting programmed cell death pathways as an anti-tumour agent. Cell Prolif. 45 (2012), 499–507.
-
(2012)
Cell Prolif.
, vol.45
, pp. 499-507
-
-
Liu, Z.1
Ouyang, L.2
Peng, H.3
Zhang, W.Z.4
-
26
-
-
79953029230
-
Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics
-
[26] Li, C.Y., Wang, E.Q., Cheng, Y., Bao, J.K., Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics. Int. J. Biochem. Cell Biol. 43 (2011), 701–704.
-
(2011)
Int. J. Biochem. Cell Biol.
, vol.43
, pp. 701-704
-
-
Li, C.Y.1
Wang, E.Q.2
Cheng, Y.3
Bao, J.K.4
-
27
-
-
84859148351
-
Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein
-
127ra38
-
[27] Zhen, T., Wu, C.F., Liu, P., Wu, H.Y., Zhou, G.B., Lu, Y., Liu, J.X., Liang, Y., Li, K.K., Wang, Y.Y., Xie, Y.Y., He, M.M., Cao, H.M., Zhang, W.N., Chen, L.M., Petrie, K., Chen, S.J., Chen, Z., Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci. Transl. Med., 4, 2012 127ra38.
-
(2012)
Sci. Transl. Med.
, vol.4
-
-
Zhen, T.1
Wu, C.F.2
Liu, P.3
Wu, H.Y.4
Zhou, G.B.5
Lu, Y.6
Liu, J.X.7
Liang, Y.8
Li, K.K.9
Wang, Y.Y.10
Xie, Y.Y.11
He, M.M.12
Cao, H.M.13
Zhang, W.N.14
Chen, L.M.15
Petrie, K.16
Chen, S.J.17
Chen, Z.18
-
28
-
-
34147131374
-
Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo
-
[28] Zhou, G.B., Kang, H., Wang, L., Gao, L., Liu, P., Xie, J., Zhang, F.X., Weng, X.Q., Shen, Z.X., Chen, J., Gu, L.J., Yan, M., Zhang, D.E., Chen, S.J., Wang, Z.Y., Chen, Z., Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood 109 (2007), 3441–3450.
-
(2007)
Blood
, vol.109
, pp. 3441-3450
-
-
Zhou, G.B.1
Kang, H.2
Wang, L.3
Gao, L.4
Liu, P.5
Xie, J.6
Zhang, F.X.7
Weng, X.Q.8
Shen, Z.X.9
Chen, J.10
Gu, L.J.11
Yan, M.12
Zhang, D.E.13
Chen, S.J.14
Wang, Z.Y.15
Chen, Z.16
-
29
-
-
84905995986
-
Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S
-
[29] Weng, H., Huang, H., Dong, B., Zhao, P., Zhou, H., Qu, L., Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res. 74 (2014), 4409–4419.
-
(2014)
Cancer Res.
, vol.74
, pp. 4409-4419
-
-
Weng, H.1
Huang, H.2
Dong, B.3
Zhao, P.4
Zhou, H.5
Qu, L.6
-
30
-
-
84862731787
-
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis
-
[30] Huang, H.L., Weng, H.Y., Wang, L.Q., Yu, C.H., Huang, Q.J., Zhao, P.P., Wen, J.Z., Zhou, H., Qu, L.H., Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol. Cancer. Ther. 11 (2012), 1155–1165.
-
(2012)
Mol. Cancer. Ther.
, vol.11
, pp. 1155-1165
-
-
Huang, H.L.1
Weng, H.Y.2
Wang, L.Q.3
Yu, C.H.4
Huang, Q.J.5
Zhao, P.P.6
Wen, J.Z.7
Zhou, H.8
Qu, L.H.9
-
31
-
-
18044387257
-
Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways
-
[31] Ikezoe, T., Yang, Y., Bandobashi, K., Saito, T., Takemoto, S., Machida, H., Togitani, K., Koeffler, H.P., Taguchi, H., Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-kappa B signal pathways. Mol. Cancer Ther. 4 (2005), 578–586.
-
(2005)
Mol. Cancer Ther.
, vol.4
, pp. 578-586
-
-
Ikezoe, T.1
Yang, Y.2
Bandobashi, K.3
Saito, T.4
Takemoto, S.5
Machida, H.6
Togitani, K.7
Koeffler, H.P.8
Taguchi, H.9
-
32
-
-
65249128643
-
Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells
-
[32] Cheng, Y., Qiu, F., Ikejima, T., Molecular mechanisms of oridonin-induced apoptosis and autophagy in murine fibrosarcoma L929 cells. Autophagy 5 (2009), 430–431.
-
(2009)
Autophagy
, vol.5
, pp. 430-431
-
-
Cheng, Y.1
Qiu, F.2
Ikejima, T.3
-
33
-
-
77953359873
-
Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways
-
[33] Kang, N., Zhang, J.H., Qiu, F., Tashiro, S., Onodera, S., Ikejima, T., Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett. 294 (2010), 147–158.
-
(2010)
Cancer Lett.
, vol.294
, pp. 147-158
-
-
Kang, N.1
Zhang, J.H.2
Qiu, F.3
Tashiro, S.4
Onodera, S.5
Ikejima, T.6
-
34
-
-
84902248209
-
Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis
-
[34] Bohanon, F.J., Wang, X., Ding, C., Ding, Y., Radhakrishnan, G.L., Rastellini, C., Zhou, J., Radhakrishnan, R.S., Oridonin inhibits hepatic stellate cell proliferation and fibrogenesis. J. Surg. Res. 190 (2014), 55–63.
-
(2014)
J. Surg. Res.
, vol.190
, pp. 55-63
-
-
Bohanon, F.J.1
Wang, X.2
Ding, C.3
Ding, Y.4
Radhakrishnan, G.L.5
Rastellini, C.6
Zhou, J.7
Radhakrishnan, R.S.8
-
35
-
-
84863811994
-
Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells
-
[35] Li, X., Li, X., Wang, J., Ye, Z., Li, J.C., Oridonin up-regulates expression of P21 and induces autophagy and apoptosis in human prostate cancer cells. Int. J. Biol. Sci. 8 (2012), 901–912.
-
(2012)
Int. J. Biol. Sci.
, vol.8
, pp. 901-912
-
-
Li, X.1
Li, X.2
Wang, J.3
Ye, Z.4
Li, J.C.5
-
36
-
-
84880994584
-
The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells
-
[36] Kwan, H.Y., Yang, Z., Fong, W.F., Hu, Y.M., Yu, Z.L., Hsiao, W.L., The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells. J. Gastroenterol. 48 (2013), 182–192.
-
(2013)
J. Gastroenterol.
, vol.48
, pp. 182-192
-
-
Kwan, H.Y.1
Yang, Z.2
Fong, W.F.3
Hu, Y.M.4
Yu, Z.L.5
Hsiao, W.L.6
-
37
-
-
84907943686
-
Polypharmacology: challenges and opportunities in drug discovery
-
[37] Anighoro, A., Bajorath, J., Rastelli, G., Polypharmacology: challenges and opportunities in drug discovery. J. Med. Chem. 57 (2014), 7874–7887.
-
(2014)
J. Med. Chem.
, vol.57
, pp. 7874-7887
-
-
Anighoro, A.1
Bajorath, J.2
Rastelli, G.3
-
38
-
-
84871967576
-
Polypharmacology: drug discovery for the future
-
[38] Reddy, A.S., Zhang, S., Polypharmacology: drug discovery for the future. Expert Rev. Clin. Pharmacol. 6 (2013), 41–47.
-
(2013)
Expert Rev. Clin. Pharmacol.
, vol.6
, pp. 41-47
-
-
Reddy, A.S.1
Zhang, S.2
-
39
-
-
60349085032
-
Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells
-
[39] Cheng, Y., Qiu, F., Ye, Y.C., Guo, Z.M., Tashiro, S., Onodera, S., Ikejima, T., Autophagy inhibits reactive oxygen species-mediated apoptosis via activating p38-nuclear factor-kappa B survival pathways in oridonin-treated murine fibrosarcoma L929 cells. FEBS J. 276 (2009), 1291–1306.
-
(2009)
FEBS J.
, vol.276
, pp. 1291-1306
-
-
Cheng, Y.1
Qiu, F.2
Ye, Y.C.3
Guo, Z.M.4
Tashiro, S.5
Onodera, S.6
Ikejima, T.7
-
40
-
-
54149084936
-
Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response
-
[40] Du, Y., Villeneuve, N.F., Wang, X.J., Sun, Z., Chen, W., Li, J., Lou, H., Wong, P.K., Zhang, D.D., Oridonin confers protection against arsenic-induced toxicity through activation of the Nrf2-mediated defensive response. Environ. Health Persp. 116 (2008), 1154–1161.
-
(2008)
Environ. Health Persp.
, vol.116
, pp. 1154-1161
-
-
Du, Y.1
Villeneuve, N.F.2
Wang, X.J.3
Sun, Z.4
Chen, W.5
Li, J.6
Lou, H.7
Wong, P.K.8
Zhang, D.D.9
-
41
-
-
84891146250
-
Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis
-
[41] Zhang, Z.Y., Daniels, R., Schluesener, H.J., Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J. Cell Mol. Med. 17 (2013), 1566–1576.
-
(2013)
J. Cell Mol. Med.
, vol.17
, pp. 1566-1576
-
-
Zhang, Z.Y.1
Daniels, R.2
Schluesener, H.J.3
-
42
-
-
84905983897
-
Oridonin attenuates Aβ1–42-induced neuroinflammation and inhibits NF-κB pathway
-
[42] Wang, S., Yang, H., Yu, L., Jin, J., Qian, L., Zhao, H., Xu, Y., Zhu, X., Oridonin attenuates Aβ1–42-induced neuroinflammation and inhibits NF-κB pathway. PLoS One, 9, 2014, e104745.
-
(2014)
PLoS One
, vol.9
, pp. e104745
-
-
Wang, S.1
Yang, H.2
Yu, L.3
Jin, J.4
Qian, L.5
Zhao, H.6
Xu, Y.7
Zhu, X.8
-
43
-
-
84867034260
-
Role of nrf2 in oxidative stress and toxicity
-
[43] Ma, Q., Role of nrf2 in oxidative stress and toxicity. Annu. Rev. Pharmacol. Toxicol. 53 (2013), 401–426.
-
(2013)
Annu. Rev. Pharmacol. Toxicol.
, vol.53
, pp. 401-426
-
-
Ma, Q.1
-
44
-
-
84892441231
-
Screening of natural compounds as activators of the keap1-nrf2 pathway
-
[44] Wu, K.C., McDonald, P.R., Liu, J., Klaassen, C.D., Screening of natural compounds as activators of the keap1-nrf2 pathway. Planta Med. 80 (2014), 97–104.
-
(2014)
Planta Med.
, vol.80
, pp. 97-104
-
-
Wu, K.C.1
McDonald, P.R.2
Liu, J.3
Klaassen, C.D.4
-
45
-
-
33847050801
-
Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway
-
[45] Kensler, T.W., Wakabayashi, N., Biswal, S., Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47 (2007), 89–116.
-
(2007)
Annu. Rev. Pharmacol. Toxicol.
, vol.47
, pp. 89-116
-
-
Kensler, T.W.1
Wakabayashi, N.2
Biswal, S.3
-
46
-
-
79960060305
-
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
-
[46] DeNicola, G.M., Karreth, F.A., Humpton, T.J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K.H., Yeo, C.J., Calhoun, E.S., Scrimieri, F., Winter, J.M., Hruban, R.H., Iacobuzio-Donahue, C., Kern, S.E., Blair, I.A., Tuveson, D.A., Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475 (2011), 106–109.
-
(2011)
Nature
, vol.475
, pp. 106-109
-
-
DeNicola, G.M.1
Karreth, F.A.2
Humpton, T.J.3
Gopinathan, A.4
Wei, C.5
Frese, K.6
Mangal, D.7
Yu, K.H.8
Yeo, C.J.9
Calhoun, E.S.10
Scrimieri, F.11
Winter, J.M.12
Hruban, R.H.13
Iacobuzio-Donahue, C.14
Kern, S.E.15
Blair, I.A.16
Tuveson, D.A.17
-
47
-
-
84864348569
-
NRF2 and cancer: the good, the bad and the importance of context
-
[47] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer 12 (2012), 564–571.
-
(2012)
Nat. Rev. Cancer
, vol.12
, pp. 564-571
-
-
Sporn, M.B.1
Liby, K.T.2
-
48
-
-
84867041441
-
Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2
-
[48] Ma, Q., He, X., Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2. Pharmacol. Rev. 64 (2012), 1055–1081.
-
(2012)
Pharmacol. Rev.
, vol.64
, pp. 1055-1081
-
-
Ma, Q.1
He, X.2
-
49
-
-
33751361646
-
Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma
-
[49] Xu, W., Sun, J., Zhang, T.T., Ma, B., Cui, S.M., Chen, D.W., He, Z.G., Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma. Acta Pharmacol. Sin. 27 (2006), 1642–1646.
-
(2006)
Acta Pharmacol. Sin.
, vol.27
, pp. 1642-1646
-
-
Xu, W.1
Sun, J.2
Zhang, T.T.3
Ma, B.4
Cui, S.M.5
Chen, D.W.6
He, Z.G.7
-
50
-
-
48649094535
-
Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates
-
[50] Xu, J., Yang, J., Ran, Q., Wang, L., Liu, J., Wang, Z., Wu, X., Hua, W., Yuan, S., Zhang, L., Shen, M., Ding, Y., Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates. Bioorg. Med. Chem. Lett. 18 (2008), 4741–4744.
-
(2008)
Bioorg. Med. Chem. Lett.
, vol.18
, pp. 4741-4744
-
-
Xu, J.1
Yang, J.2
Ran, Q.3
Wang, L.4
Liu, J.5
Wang, Z.6
Wu, X.7
Hua, W.8
Yuan, S.9
Zhang, L.10
Shen, M.11
Ding, Y.12
-
51
-
-
84879588528
-
Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility
-
[51] Ding, C., Zhang, Y., Chen, H., Yang, Z., Wild, C., Chu, L., Liu, H., Shen, Q., Zhou, J., Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J. Med. Chem. 56 (2013), 5048–5058.
-
(2013)
J. Med. Chem.
, vol.56
, pp. 5048-5058
-
-
Ding, C.1
Zhang, Y.2
Chen, H.3
Yang, Z.4
Wild, C.5
Chu, L.6
Liu, H.7
Shen, Q.8
Zhou, J.9
-
52
-
-
79956027640
-
Synthesis and anti-tumor activity of 14-O-derivatives of natural oridonin
-
[52] Wang, L., Ran, Q., Li, D., Yao, H., Zhang, Y., Yuan, S., Zhang, L., Shen, M., Xu, J., Synthesis and anti-tumor activity of 14-O-derivatives of natural oridonin. Chin. J. Nat. Med. 9 (2011), 194–198.
-
(2011)
Chin. J. Nat. Med.
, vol.9
, pp. 194-198
-
-
Wang, L.1
Ran, Q.2
Li, D.3
Yao, H.4
Zhang, Y.5
Yuan, S.6
Zhang, L.7
Shen, M.8
Xu, J.9
-
53
-
-
49449090229
-
Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid
-
[53] Chen, L., Zhang, Y., Kong, X., Lan, E., Huang, Z., Peng, S., Kaufman, D.L., Tian, J., Design, synthesis, and antihepatocellular carcinoma activity of nitric oxide releasing derivatives of oleanolic acid. J. Med. Chem. 51 (2008), 4834–4838.
-
(2008)
J. Med. Chem.
, vol.51
, pp. 4834-4838
-
-
Chen, L.1
Zhang, Y.2
Kong, X.3
Lan, E.4
Huang, Z.5
Peng, S.6
Kaufman, D.L.7
Tian, J.8
-
54
-
-
84924666732
-
Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer
-
[54] Ai, Y., Kang, F., Huang, Z., Xue, X., Lai, Y., Peng, S., Tian, J., Zhang, Y., Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer. J. Med. Chem. 58 (2015), 2452–2464.
-
(2015)
J. Med. Chem.
, vol.58
, pp. 2452-2464
-
-
Ai, Y.1
Kang, F.2
Huang, Z.3
Xue, X.4
Lai, Y.5
Peng, S.6
Tian, J.7
Zhang, Y.8
-
55
-
-
34250219551
-
Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship
-
[55] Rachid, Z., Brahimi, F., Qiu, Q., Williams, C., Hartley, J.M., Hartley, J.A., Jean-Claude, B.J., Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. J. Med. Chem. 50 (2007), 2605–2608.
-
(2007)
J. Med. Chem.
, vol.50
, pp. 2605-2608
-
-
Rachid, Z.1
Brahimi, F.2
Qiu, Q.3
Williams, C.4
Hartley, J.M.5
Hartley, J.A.6
Jean-Claude, B.J.7
-
56
-
-
84889241501
-
A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers
-
[56] Millard, M., Gallagher, J.D., Olenyuk, B.Z., Neamati, N., A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. J. Med. Chem. 56 (2013), 9170–9179.
-
(2013)
J. Med. Chem.
, vol.56
, pp. 9170-9179
-
-
Millard, M.1
Gallagher, J.D.2
Olenyuk, B.Z.3
Neamati, N.4
-
57
-
-
84862995584
-
Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents
-
[57] Li, D., Wang, L., Cai, H., Zhang, Y., Xu, J., Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents. Molecules 17 (2012), 7556–7568.
-
(2012)
Molecules
, vol.17
, pp. 7556-7568
-
-
Li, D.1
Wang, L.2
Cai, H.3
Zhang, Y.4
Xu, J.5
-
58
-
-
84904334900
-
Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates
-
[58] Xu, S., Pei, L., Wang, C., Zhang, Y.K., Li, D., Yao, H., Wu, X., Chen, Z.S., Sun, Y., Xu, J., Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates. ACS Med. Chem. Lett. 5 (2014), 797–802.
-
(2014)
ACS Med. Chem. Lett.
, vol.5
, pp. 797-802
-
-
Xu, S.1
Pei, L.2
Wang, C.3
Zhang, Y.K.4
Li, D.5
Yao, H.6
Wu, X.7
Chen, Z.S.8
Sun, Y.9
Xu, J.10
-
59
-
-
84901391079
-
Derivation of oridonin with bioreduction-responsive disulfide bond
-
[59] Du, M., Guo, Q., Feng, H., Lu, G., Huang, X., Derivation of oridonin with bioreduction-responsive disulfide bond. Chin. J. Chem. 32 (2014), 448–453.
-
(2014)
Chin. J. Chem.
, vol.32
, pp. 448-453
-
-
Du, M.1
Guo, Q.2
Feng, H.3
Lu, G.4
Huang, X.5
-
60
-
-
84899038383
-
Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates
-
[60] Shen, J., Zhang, D., Zhao, Z., Jia, L., Zheng, D., Liu, G., Hao, L., Zhang, Q., Tian, X., Li, C., Guo, H., Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates. Int. J. Pharm. 456 (2013), 80–86.
-
(2013)
Int. J. Pharm.
, vol.456
, pp. 80-86
-
-
Shen, J.1
Zhang, D.2
Zhao, Z.3
Jia, L.4
Zheng, D.5
Liu, G.6
Hao, L.7
Zhang, Q.8
Tian, X.9
Li, C.10
Guo, H.11
-
61
-
-
70349988803
-
PEG conjugates in clinical development or use as anticancer agents: an overview
-
[61] Pasut, G., Veronese, F.M., PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 61 (2009), 1177–1188.
-
(2009)
Adv. Drug Deliv. Rev.
, vol.61
, pp. 1177-1188
-
-
Pasut, G.1
Veronese, F.M.2
-
62
-
-
0035816168
-
PEG drugs: an overview
-
[62] Greenwald, R.B., PEG drugs: an overview. J. Control. Release 74 (2001), 159–171.
-
(2001)
J. Control. Release
, vol.74
, pp. 159-171
-
-
Greenwald, R.B.1
-
63
-
-
84861468033
-
Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro
-
[63] Xue, B., Wang, Y., Tang, X., Xie, P., Wang, Y., Luo, F., Wu, C., Qian, Z., Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro. J. Biomed. Nanotechnol. 8 (2012), 80–89.
-
(2012)
J. Biomed. Nanotechnol.
, vol.8
, pp. 80-89
-
-
Xue, B.1
Wang, Y.2
Tang, X.3
Xie, P.4
Wang, Y.5
Luo, F.6
Wu, C.7
Qian, Z.8
-
64
-
-
84963877901
-
Oridonin derivative ameliorates experimental colitis by inhibiting activated T cells and translocation of nuclear factor-kappa B
-
PMID: 26718746
-
[64] Liu, Q.Q., Wang, H.L., Chen, K., Wang, S.B., Xu, Y., Ye, Q., Sun, Y.W., Oridonin derivative ameliorates experimental colitis by inhibiting activated T cells and translocation of nuclear factor-kappa B. J. Dig. Dis., 2015, 10.1111/1751-2980.12314 PMID: 26718746.
-
(2015)
J. Dig. Dis.
-
-
Liu, Q.Q.1
Wang, H.L.2
Chen, K.3
Wang, S.B.4
Xu, Y.5
Ye, Q.6
Sun, Y.W.7
-
65
-
-
84907979062
-
ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids
-
[65] Ding, C., Wang, L., Chen, H., Wild, C., Ye, N., Ding, Y., Wang, T., White, M.A., Shen, Q., Zhou, J., ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids. Org. Biomol. Chem. 12 (2014), 8442–8452.
-
(2014)
Org. Biomol. Chem.
, vol.12
, pp. 8442-8452
-
-
Ding, C.1
Wang, L.2
Chen, H.3
Wild, C.4
Ye, N.5
Ding, Y.6
Wang, T.7
White, M.A.8
Shen, Q.9
Zhou, J.10
-
66
-
-
84887892414
-
Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis
-
[66] Ding, C., Zhang, Y., Chen, H., Yang, Z., Wild, C., Ye, N., Ester, C.D., Xiong, A., White, M.A., Shen, Q., Zhou, J., Oridonin ring A-based diverse constructions of enone functionality: identification of novel dienone analogues effective for highly aggressive breast cancer by inducing apoptosis. J. Med. Chem. 56 (2013), 8814–8825.
-
(2013)
J. Med. Chem.
, vol.56
, pp. 8814-8825
-
-
Ding, C.1
Zhang, Y.2
Chen, H.3
Yang, Z.4
Wild, C.5
Ye, N.6
Ester, C.D.7
Xiong, A.8
White, M.A.9
Shen, Q.10
Zhou, J.11
-
67
-
-
84880554110
-
Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position
-
[67] Ding, C., Zhang, Y., Chen, H., Wild, C., Wang, T., White, M.A., Shen, Q., Zhou, J., Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position. Org. Lett. 15 (2013), 3718–3721.
-
(2013)
Org. Lett.
, vol.15
, pp. 3718-3721
-
-
Ding, C.1
Zhang, Y.2
Chen, H.3
Wild, C.4
Wang, T.5
White, M.A.6
Shen, Q.7
Zhou, J.8
-
68
-
-
84904357195
-
Profile and potential of ixabepilone in the treatment of pancreatic cancer
-
[68] Smaglo, B.G., Pishvaian, M.J., Profile and potential of ixabepilone in the treatment of pancreatic cancer. Drug Des. Devel. Ther. 8 (2014), 923–930.
-
(2014)
Drug Des. Devel. Ther.
, vol.8
, pp. 923-930
-
-
Smaglo, B.G.1
Pishvaian, M.J.2
-
69
-
-
84903738409
-
Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds
-
[69] Zhao, G.D., Wan, R.Z., Liu, Z.P., Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds. Curr. Med. Chem. 21 (2014), 2691–2701.
-
(2014)
Curr. Med. Chem.
, vol.21
, pp. 2691-2701
-
-
Zhao, G.D.1
Wan, R.Z.2
Liu, Z.P.3
-
70
-
-
79953704034
-
Epothilones in the treatment of ovarian cancer
-
[70] Diaz-Padilla, I., Oza, A.M., Epothilones in the treatment of ovarian cancer. Future Oncol. 7 (2011), 559–568.
-
(2011)
Future Oncol.
, vol.7
, pp. 559-568
-
-
Diaz-Padilla, I.1
Oza, A.M.2
-
71
-
-
84958900764
-
Direct activation of Bax protein for cancer therapy
-
[71] Liu, Z., Ding, Y., Ye, N., Wild, C., Chen, H., Zhou, J., Direct activation of Bax protein for cancer therapy. Med. Res. Rev. 36 (2015), 313–341.
-
(2015)
Med. Res. Rev.
, vol.36
, pp. 313-341
-
-
Liu, Z.1
Ding, Y.2
Ye, N.3
Wild, C.4
Chen, H.5
Zhou, J.6
-
72
-
-
84923370451
-
Small-molecule Bax agonists for cancer therapy
-
[72] Xin, M., Li, R., Xie, M., Park, D., Owonikoko, T.K., Sica, G.L., Corsino, P.E., Zhou, J., Ding, C., White, M.A., Magis, A.T., Ramalingam, S.S., Curran, W.J., Khuri, F.R., Deng, X., Small-molecule Bax agonists for cancer therapy. Nat. Commun., 5, 2014, 4935.
-
(2014)
Nat. Commun.
, vol.5
, pp. 4935
-
-
Xin, M.1
Li, R.2
Xie, M.3
Park, D.4
Owonikoko, T.K.5
Sica, G.L.6
Corsino, P.E.7
Zhou, J.8
Ding, C.9
White, M.A.10
Magis, A.T.11
Ramalingam, S.S.12
Curran, W.J.13
Khuri, F.R.14
Deng, X.15
-
73
-
-
84949669843
-
BH4 domain of Bcl-2 as a novel target for cancer therapy
-
PMID: 26631752
-
[73] Liu, Z., Wild, C., Ding, Y., Ye, N., Chen, H., Wold, E.A., Zhou, J., BH4 domain of Bcl-2 as a novel target for cancer therapy. Drug Discov. Today, 2015, 10.1016/j.drudis.2015.11.008 PMID: 26631752.
-
(2015)
Drug Discov. Today
-
-
Liu, Z.1
Wild, C.2
Ding, Y.3
Ye, N.4
Chen, H.5
Wold, E.A.6
Zhou, J.7
-
74
-
-
84930573524
-
Small-molecule Bcl2 BH4 antagonist for lung cancer therapy
-
[74] Han, B., Park, D., Li, R., Xie, M., Owonikoko, T.K., Zhang, G., Sica, G.L., Ding, C., Zhou, J., Magis, A.T., Chen, Z.G., Shin, D.M., Ramalingam, S.S., Khuri, F.R., Curran, W.J., Deng, X., Small-molecule Bcl2 BH4 antagonist for lung cancer therapy. Cancer Cell 27 (2015), 852–863.
-
(2015)
Cancer Cell
, vol.27
, pp. 852-863
-
-
Han, B.1
Park, D.2
Li, R.3
Xie, M.4
Owonikoko, T.K.5
Zhang, G.6
Sica, G.L.7
Ding, C.8
Zhou, J.9
Magis, A.T.10
Chen, Z.G.11
Shin, D.M.12
Ramalingam, S.S.13
Khuri, F.R.14
Curran, W.J.15
Deng, X.16
-
75
-
-
84901393389
-
Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review
-
[75] Polastro, L., Aftimos, P.G., Awada, A., Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review. Expert Rev. Anticancer Ther. 14 (2014), 649–665.
-
(2014)
Expert Rev. Anticancer Ther.
, vol.14
, pp. 649-665
-
-
Polastro, L.1
Aftimos, P.G.2
Awada, A.3
-
76
-
-
33646501280
-
A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma, Invest
-
[76] Ajani, J.A., Jiang, Y., Faust, J., Chang, B.B., Ho, L., Yao, J.C., Rousey, S., Dakhil, S., Cherny, R.C., Craig, C., Bleyer, A., A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma, Invest. New Drugs 24 (2006), 353–357.
-
(2006)
New Drugs
, vol.24
, pp. 353-357
-
-
Ajani, J.A.1
Jiang, Y.2
Faust, J.3
Chang, B.B.4
Ho, L.5
Yao, J.C.6
Rousey, S.7
Dakhil, S.8
Cherny, R.C.9
Craig, C.10
Bleyer, A.11
-
77
-
-
17144381253
-
Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma
-
[77] Shiraki, T., Kamiya, N., Shiki, S., Kodama, T.S., Kakizuka, A., Jingami, H., Alpha,beta-unsaturated ketone is a core moiety of natural ligands for covalent binding to peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 280 (2005), 14145–14153.
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 14145-14153
-
-
Shiraki, T.1
Kamiya, N.2
Shiki, S.3
Kodama, T.S.4
Kakizuka, A.5
Jingami, H.6
-
78
-
-
0034597578
-
Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages
-
[78] Honda, T., Rounds, B.V., Bore, L., Finlay, H.J., Favaloro, F.G. Jr., Suh, N., Wang, Y., Sporn, M.B., Gribble, G.W., Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem. 43 (2000), 4233–4246.
-
(2000)
J. Med. Chem.
, vol.43
, pp. 4233-4246
-
-
Honda, T.1
Rounds, B.V.2
Bore, L.3
Finlay, H.J.4
Favaloro, F.G.5
Suh, N.6
Wang, Y.7
Sporn, M.B.8
Gribble, G.W.9
-
79
-
-
84903534871
-
Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity
-
[79] Li, X., Zuo, Y., Tang, G., Wang, Y., Zhou, Y., Wang, X., Guo, T., Xia, M., Ding, N., Pan, Z., Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J. Med. Chem. 57 (2014), 5112–5128.
-
(2014)
J. Med. Chem.
, vol.57
, pp. 5112-5128
-
-
Li, X.1
Zuo, Y.2
Tang, G.3
Wang, Y.4
Zhou, Y.5
Wang, X.6
Guo, T.7
Xia, M.8
Ding, N.9
Pan, Z.10
-
80
-
-
0348109450
-
The growing impact of click chemistry on drug discovery
-
[80] Kolb, H.C., Sharpless, K.B., The growing impact of click chemistry on drug discovery. Drug Discov. Today 8 (2003), 1128–1137.
-
(2003)
Drug Discov. Today
, vol.8
, pp. 1128-1137
-
-
Kolb, H.C.1
Sharpless, K.B.2
-
81
-
-
80053528741
-
Click chemistry: 1,2,3-triazoles as pharmacophores
-
[81] Agalave, S.G., Maujan, S.R., Pore, V.S., Click chemistry: 1,2,3-triazoles as pharmacophores. Chem. Asian J. 6 (2011), 2696–2718.
-
(2011)
Chem. Asian J.
, vol.6
, pp. 2696-2718
-
-
Agalave, S.G.1
Maujan, S.R.2
Pore, V.S.3
-
82
-
-
84877835595
-
Click chemistry for drug development and diverse chemical-biology applications
-
[82] Thirumurugan, P., Matosiuk, D., Jozwiak, K., Click chemistry for drug development and diverse chemical-biology applications. Chem. Rev. 113 (2013), 4905–4979.
-
(2013)
Chem. Rev.
, vol.113
, pp. 4905-4979
-
-
Thirumurugan, P.1
Matosiuk, D.2
Jozwiak, K.3
-
83
-
-
85043147568
-
-
Synthesis and derivatization of an ent-kaurane diterpenoid, Chinese Patent (2011) CN 102584760 A.
-
[83] F.J. Nan, Y.M. Zhang, H.N. Liu, J. Ding, L.H. Meng, C.H. Xu, Synthesis and derivatization of an ent-kaurane diterpenoid, Chinese Patent (2011) CN 102584760 A.
-
-
-
Nan, F.J.1
Zhang, Y.M.2
Liu, H.N.3
Ding, J.4
Meng, L.H.5
Xu, C.H.6
-
84
-
-
33646460405
-
Bisrubescensins A-C: three new dimeric ent-kauranoids isolated from Isodon rubescens
-
[84] Huang, S.X., Xiao, W.L., Li, L.M., Li, S.H., Zhou, Y., Ding, L.S., Lou, L.G., Sun, H.D., Bisrubescensins A-C: three new dimeric ent-kauranoids isolated from Isodon rubescens. Org. Lett. 8 (2006), 1157–1160.
-
(2006)
Org. Lett.
, vol.8
, pp. 1157-1160
-
-
Huang, S.X.1
Xiao, W.L.2
Li, L.M.3
Li, S.H.4
Zhou, Y.5
Ding, L.S.6
Lou, L.G.7
Sun, H.D.8
-
85
-
-
77954061481
-
Cytotoxic ent-kaurane diterpenoids from Isodon rubescens var. lushiensis
-
[85] Luo, X., Pu, J.X., Xiao, W.L., Zhao, Y., Gao, X.M., Li, X.N., Zhang, H.B., Wang, Y.Y., Li, Y., Sun, H.D., Cytotoxic ent-kaurane diterpenoids from Isodon rubescens var. lushiensis. J. Nat. Prod. 73 (2010), 1112–1116.
-
(2010)
J. Nat. Prod.
, vol.73
, pp. 1112-1116
-
-
Luo, X.1
Pu, J.X.2
Xiao, W.L.3
Zhao, Y.4
Gao, X.M.5
Li, X.N.6
Zhang, H.B.7
Wang, Y.Y.8
Li, Y.9
Sun, H.D.10
-
86
-
-
70350491038
-
ent-Kaurane and cembrane diterpenoids from Isodon sculponeatus and their cytotoxicity
-
[86] Li, L.M., Li, G.Y., Pu, J.X., Xiao, W.L., Ding, L.S., Sun, H.D., ent-Kaurane and cembrane diterpenoids from Isodon sculponeatus and their cytotoxicity. J. Nat. Prod. 72 (2009), 1851–1856.
-
(2009)
J. Nat. Prod.
, vol.72
, pp. 1851-1856
-
-
Li, L.M.1
Li, G.Y.2
Pu, J.X.3
Xiao, W.L.4
Ding, L.S.5
Sun, H.D.6
-
87
-
-
78650227978
-
Structure and cytotoxicity of diterpenoids from Isodon eriocalyx
-
[87] Li, X.N., Pu, J.X., Du, X., Lou, L.G., Li, L.M., Huang, S.X., Zhao, B., Zhang, M., He, F., Luo, X., Xiao, W.L., Sun, H.D., Structure and cytotoxicity of diterpenoids from Isodon eriocalyx. J. Nat. Prod. 73 (2010), 1803–1809.
-
(2010)
J. Nat. Prod.
, vol.73
, pp. 1803-1809
-
-
Li, X.N.1
Pu, J.X.2
Du, X.3
Lou, L.G.4
Li, L.M.5
Huang, S.X.6
Zhao, B.7
Zhang, M.8
He, F.9
Luo, X.10
Xiao, W.L.11
Sun, H.D.12
-
88
-
-
78650449672
-
6,7-seco-ent-kaurane diterpenoids from Isodon sculponeatus with cytotoxic activity
-
[88] Li, X., Pu, J.X., Weng, Z.Y., Zhao, Y., Zhao, Y., Xiao, W.L., Sun, H.D., 6,7-seco-ent-kaurane diterpenoids from Isodon sculponeatus with cytotoxic activity. Chem. Biodivers. 7 (2010), 2888–2896.
-
(2010)
Chem. Biodivers.
, vol.7
, pp. 2888-2896
-
-
Li, X.1
Pu, J.X.2
Weng, Z.Y.3
Zhao, Y.4
Zhao, Y.5
Xiao, W.L.6
Sun, H.D.7
-
89
-
-
84860351057
-
The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents
-
[89] Wang, L., Li, D., Xu, S., Cai, H., Yao, H., Zhang, Y., Jiang, J., Xu, J., The conversion of oridonin to spirolactone-type or enmein-type diterpenoid: synthesis and biological evaluation of ent-6,7-seco-oridonin derivatives as novel potential anticancer agents. Eur. J. Med. Chem. 52 (2012), 242–250.
-
(2012)
Eur. J. Med. Chem.
, vol.52
, pp. 242-250
-
-
Wang, L.1
Li, D.2
Xu, S.3
Cai, H.4
Yao, H.5
Zhang, Y.6
Jiang, J.7
Xu, J.8
-
90
-
-
84871410742
-
Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells
-
[90] Li, D., Cai, H., Jiang, B., Liu, G., Wang, Y., Wang, L., Yao, H., Wu, X., Sun, Y., Xu, J., Synthesis of spirolactone-type diterpenoid derivatives from kaurene-type oridonin with improved antiproliferative effects and their apoptosis-inducing activity in human hepatoma Bel-7402 cells. Eur. J. Med. Chem. 59 (2013), 322–328.
-
(2013)
Eur. J. Med. Chem.
, vol.59
, pp. 322-328
-
-
Li, D.1
Cai, H.2
Jiang, B.3
Liu, G.4
Wang, Y.5
Wang, L.6
Yao, H.7
Wu, X.8
Sun, Y.9
Xu, J.10
-
91
-
-
84877025427
-
Enmein-type diterpenoid analogs from natural kaurene-type oridonin: synthesis and their antitumor biological evaluation
-
[91] Li, D., Xu, S., Cai, H., Pei, L., Zhang, H., Wang, L., Yao, H., Wu, X., Jiang, J., Sun, Y., Xu, J., Enmein-type diterpenoid analogs from natural kaurene-type oridonin: synthesis and their antitumor biological evaluation. Eur. J. Med. Chem. 64 (2013), 215–221.
-
(2013)
Eur. J. Med. Chem.
, vol.64
, pp. 215-221
-
-
Li, D.1
Xu, S.2
Cai, H.3
Pei, L.4
Zhang, H.5
Wang, L.6
Yao, H.7
Wu, X.8
Jiang, J.9
Sun, Y.10
Xu, J.11
-
92
-
-
84877020396
-
Library construction and biological evaluation of enmein-type diterpenoid analogues as potential anticancer agents
-
[92] Li, D., Xu, S., Cai, H., Pei, L., Wang, L., Wu, X., Yao, H., Jiang, J., Sun, Y., Xu, J., Library construction and biological evaluation of enmein-type diterpenoid analogues as potential anticancer agents. ChemMedChem 8 (2013), 812–818.
-
(2013)
ChemMedChem
, vol.8
, pp. 812-818
-
-
Li, D.1
Xu, S.2
Cai, H.3
Pei, L.4
Wang, L.5
Wu, X.6
Yao, H.7
Jiang, J.8
Sun, Y.9
Xu, J.10
-
93
-
-
3042577557
-
Rubescensins S and T: seco-ent-kaurane diterpenoids from Isodon rubescens var. taihangensis
-
[93] Han, Q., Li, R., Zhang, J., Sun, H., Rubescensins S and T: seco-ent-kaurane diterpenoids from Isodon rubescens var. taihangensis. Helv. Chim. Acta 87 (2004), 1119–1124.
-
(2004)
Helv. Chim. Acta
, vol.87
, pp. 1119-1124
-
-
Han, Q.1
Li, R.2
Zhang, J.3
Sun, H.4
-
94
-
-
79957979055
-
Synthesis and revision of stereochemistry of rubescensin S
-
[94] Zhang, M., Zhang, Y., Lu, W., Nan, F.J., Synthesis and revision of stereochemistry of rubescensin S. Org. Biomol. Chem. 9 (2011), 4436–4439.
-
(2011)
Org. Biomol. Chem.
, vol.9
, pp. 4436-4439
-
-
Zhang, M.1
Zhang, Y.2
Lu, W.3
Nan, F.J.4
-
95
-
-
33745066452
-
New diterpenoids from Semiaquilegia adoxoides
-
[95] Niu, F., Chang, H.T., Jiang, Y., Cui, Z., Chen, F.K., Yuan, J.Z., Tu, P.F., New diterpenoids from Semiaquilegia adoxoides. J. Asian Nat. Prod. Res. 8 (2006), 87–91.
-
(2006)
J. Asian Nat. Prod. Res.
, vol.8
, pp. 87-91
-
-
Niu, F.1
Chang, H.T.2
Jiang, Y.3
Cui, Z.4
Chen, F.K.5
Yuan, J.Z.6
Tu, P.F.7
-
96
-
-
73649114917
-
Formal synthesis of semiaquilegin A
-
[96] Li, J., Jiang, Y., Li, Q., Xiao, Q., Jia, Y., Tu, P., Formal synthesis of semiaquilegin A. Tetrahedron Lett. 51 (2010), 1121–1123.
-
(2010)
Tetrahedron Lett.
, vol.51
, pp. 1121-1123
-
-
Li, J.1
Jiang, Y.2
Li, Q.3
Xiao, Q.4
Jia, Y.5
Tu, P.6
-
97
-
-
34247360358
-
Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo
-
[97] Zhou, G.B., Chen, S.J., Wang, Z.Y., Chen, Z., Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo. Cell Res. 17 (2007), 274–276.
-
(2007)
Cell Res.
, vol.17
, pp. 274-276
-
-
Zhou, G.B.1
Chen, S.J.2
Wang, Z.Y.3
Chen, Z.4
-
98
-
-
54249155522
-
Network pharmacology: the next paradigm in drug discovery
-
[98] Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4 (2008), 682–690.
-
(2008)
Nat. Chem. Biol.
, vol.4
, pp. 682-690
-
-
Hopkins, A.L.1
-
99
-
-
33751547539
-
How many drug targets are there
-
[99] Overington, J.P., Al-Lazikani, B., Hopkins, A.L., How many drug targets are there. Nat. Rev. Drug Discov. 5 (2006), 993–996.
-
(2006)
Nat. Rev. Drug Discov.
, vol.5
, pp. 993-996
-
-
Overington, J.P.1
Al-Lazikani, B.2
Hopkins, A.L.3
-
100
-
-
75149130051
-
Targeting the cancer kinome through polypharmacology
-
[100] Knight, Z.A., Lin, H., Shokat, K.M., Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10 (2010), 130–137.
-
(2010)
Nat. Rev. Cancer
, vol.10
, pp. 130-137
-
-
Knight, Z.A.1
Lin, H.2
Shokat, K.M.3
-
101
-
-
84937713453
-
Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products
-
[101] Kibble, M., Saarinen, N., Tang, J., Wennerberg, K., Makela, S., Aittokallio, T., Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat. Prod. Rep. 32 (2015), 1249–1266.
-
(2015)
Nat. Prod. Rep.
, vol.32
, pp. 1249-1266
-
-
Kibble, M.1
Saarinen, N.2
Tang, J.3
Wennerberg, K.4
Makela, S.5
Aittokallio, T.6
-
102
-
-
84911496459
-
Revealing the macromolecular targets of complex natural products
-
[102] Reker, D., Perna, A.M., Rodrigues, T., Schneider, P., Reutlinger, M., Monch, B., Koeberle, A., Lamers, C., Gabler, M., Steinmetz, H., Muller, R., Schubert-Zsilavecz, M., Werz, O., Schneider, G., Revealing the macromolecular targets of complex natural products. Nat. Chem. 6 (2014), 1072–1078.
-
(2014)
Nat. Chem.
, vol.6
, pp. 1072-1078
-
-
Reker, D.1
Perna, A.M.2
Rodrigues, T.3
Schneider, P.4
Reutlinger, M.5
Monch, B.6
Koeberle, A.7
Lamers, C.8
Gabler, M.9
Steinmetz, H.10
Muller, R.11
Schubert-Zsilavecz, M.12
Werz, O.13
Schneider, G.14
-
103
-
-
84978640737
-
A new oridonin analogue suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5
-
in press
-
[103] Wu, J., Ding, Y., Zhou, Z., Ding, C., Chen, H., Zhou, J., Chen, C., A new oridonin analogue suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Lett., 2016 in press.
-
(2016)
Cancer Lett.
-
-
Wu, J.1
Ding, Y.2
Zhou, Z.3
Ding, C.4
Chen, H.5
Zhou, J.6
Chen, C.7
-
104
-
-
84930915706
-
Targeting Kruppel-like factor 5 (KLF5) for cancer therapy
-
[104] Gao, Y., Ding, Y., Chen, H., Chen, H., Zhou, J., Targeting Kruppel-like factor 5 (KLF5) for cancer therapy. Curr. Top. Med. Chem. 15 (2015), 699–713.
-
(2015)
Curr. Top. Med. Chem.
, vol.15
, pp. 699-713
-
-
Gao, Y.1
Ding, Y.2
Chen, H.3
Chen, H.4
Zhou, J.5
-
105
-
-
85043166510
-
Targeting new regulatory mechanism of XBP1-mediated β-catenin expression associated with bladder cancer survival with a unique synthetic natural product
-
in press
-
[105] Chen, W., Zhou, J., Wu, K., Huang, J., Ding, Y., Yun, E., Wang, B., Ding, C., Hernandez, E., Santoyo, J., Chen, H., Lin, H., Sagalowsky, A., He, D., Zhou, J., Hsieh, J., Targeting new regulatory mechanism of XBP1-mediated β-catenin expression associated with bladder cancer survival with a unique synthetic natural product. Oncotarget, 2016 in press.
-
(2016)
Oncotarget
-
-
Chen, W.1
Zhou, J.2
Wu, K.3
Huang, J.4
Ding, Y.5
Yun, E.6
Wang, B.7
Ding, C.8
Hernandez, E.9
Santoyo, J.10
Chen, H.11
Lin, H.12
Sagalowsky, A.13
He, D.14
Zhou, J.15
Hsieh, J.16
-
106
-
-
84971607463
-
Probing the anticancer action of oridonin with fluorescent analogues: visualizing subcellular localization to mitochondria
-
[106] Xu, S., Luo, S., Yao, H., Cai, H., Miao, X., Wu, F., Yang, D.H., Wu, X., Xie, W., Yao, H., Chen, Z.S., Xu, J., Probing the anticancer action of oridonin with fluorescent analogues: visualizing subcellular localization to mitochondria. J. Med. Chem. 59 (2016), 5022–5034.
-
(2016)
J. Med. Chem.
, vol.59
, pp. 5022-5034
-
-
Xu, S.1
Luo, S.2
Yao, H.3
Cai, H.4
Miao, X.5
Wu, F.6
Yang, D.H.7
Wu, X.8
Xie, W.9
Yao, H.10
Chen, Z.S.11
Xu, J.12
-
107
-
-
84921533887
-
Evolutions in fragment-based drug design: the deconstruction-reconstruction approach
-
[107] Chen, H., Zhou, X., Wang, A., Zheng, Y., Gao, Y., Zhou, J., Evolutions in fragment-based drug design: the deconstruction-reconstruction approach. Drug Discov. Today 20 (2015), 105–113.
-
(2015)
Drug Discov. Today
, vol.20
, pp. 105-113
-
-
Chen, H.1
Zhou, X.2
Wang, A.3
Zheng, Y.4
Gao, Y.5
Zhou, J.6
-
108
-
-
84876079596
-
Fragment informatics and computational fragment-based drug design: an overview and update
-
[108] Sheng, C., Zhang, W., Fragment informatics and computational fragment-based drug design: an overview and update. Med. Res. Rev. 33 (2013), 554–598.
-
(2013)
Med. Res. Rev.
, vol.33
, pp. 554-598
-
-
Sheng, C.1
Zhang, W.2
-
109
-
-
33847381100
-
A decade of fragment-based drug design: strategic advances and lessons learned
-
[109] Hajduk, P.J., Greer, J., A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6 (2007), 211–219.
-
(2007)
Nat. Rev. Drug Discov.
, vol.6
, pp. 211-219
-
-
Hajduk, P.J.1
Greer, J.2
-
110
-
-
84873738776
-
Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy
-
[110] Chen, H., Yang, Z., Ding, C., Chu, L., Zhang, Y., Terry, K., Liu, H., Shen, Q., Zhou, J., Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy. Eur. J. Med. Chem. 62 (2013), 498–507.
-
(2013)
Eur. J. Med. Chem.
, vol.62
, pp. 498-507
-
-
Chen, H.1
Yang, Z.2
Ding, C.3
Chu, L.4
Zhang, Y.5
Terry, K.6
Liu, H.7
Shen, Q.8
Zhou, J.9
-
111
-
-
84873873454
-
A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents
-
[111] Chen, H., Wang, C.Z., Ding, C., Wild, C., Copits, B., Swanson, G.T., Johnson, K.M., Zhou, J., A combined bioinformatics and chemoinformatics approach for developing asymmetric bivalent AMPA receptor positive allosteric modulators as neuroprotective agents. ChemMedChem 8 (2013), 226–230.
-
(2013)
ChemMedChem
, vol.8
, pp. 226-230
-
-
Chen, H.1
Wang, C.Z.2
Ding, C.3
Wild, C.4
Copits, B.5
Swanson, G.T.6
Johnson, K.M.7
Zhou, J.8
-
112
-
-
84902175603
-
Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)
-
[112] Chen, H., Yang, Z., Ding, C., Xiong, A., Wild, C., Wang, L., Ye, N., Cai, G., Flores, R.M., Ding, Y., Shen, Q., Zhou, J., Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur. J. Med. Chem. 82 (2014), 195–203.
-
(2014)
Eur. J. Med. Chem.
, vol.82
, pp. 195-203
-
-
Chen, H.1
Yang, Z.2
Ding, C.3
Xiong, A.4
Wild, C.5
Wang, L.6
Ye, N.7
Cai, G.8
Flores, R.M.9
Ding, Y.10
Shen, Q.11
Zhou, J.12
-
113
-
-
84929377653
-
pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures
-
[113] Pires, D.E., Blundell, T.L., Ascher, D.B., pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 58 (2015), 4066–4072.
-
(2015)
J. Med. Chem.
, vol.58
, pp. 4066-4072
-
-
Pires, D.E.1
Blundell, T.L.2
Ascher, D.B.3
-
114
-
-
84873252557
-
Liposomal drug delivery systems: from concept to clinical applications
-
[114] Allen, T.M., Cullis, P.R., Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65 (2013), 36–48.
-
(2013)
Adv. Drug Deliv. Rev.
, vol.65
, pp. 36-48
-
-
Allen, T.M.1
Cullis, P.R.2
-
115
-
-
84901983377
-
pH-sensitive nano-systems for drug delivery in cancer therapy
-
[115] Liu, J., Huang, Y., Kumar, A., Tan, A., Jin, S., Mozhi, A., Liang, X.J., pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol. Adv. 32 (2014), 693–710.
-
(2014)
Biotechnol. Adv.
, vol.32
, pp. 693-710
-
-
Liu, J.1
Huang, Y.2
Kumar, A.3
Tan, A.4
Jin, S.5
Mozhi, A.6
Liang, X.J.7
-
116
-
-
84866772465
-
Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line
-
[116] Qi, X., Zhang, D., Xu, X., Feng, F., Ren, G., Chu, Q., Zhang, Q., Tian, K., Oridonin nanosuspension was more effective than free oridonin on G2/M cell cycle arrest and apoptosis in the human pancreatic cancer PANC-1 cell line. Int. J. Nanomed. 7 (2012), 1793–1804.
-
(2012)
Int. J. Nanomed.
, vol.7
, pp. 1793-1804
-
-
Qi, X.1
Zhang, D.2
Xu, X.3
Feng, F.4
Ren, G.5
Chu, Q.6
Zhang, Q.7
Tian, K.8
-
117
-
-
79960422870
-
Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice
-
[117] Lou, H., Gao, L., Wei, X., Zhang, Z., Zheng, D., Zhang, D., Zhang, X., Li, Y., Zhang, Q., Oridonin nanosuspension enhances anti-tumor efficacy in SMMC-7721 cells and H22 tumor bearing mice. Colloids Surf. B. Biointerfaces 87 (2011), 319–325.
-
(2011)
Colloids Surf. B. Biointerfaces
, vol.87
, pp. 319-325
-
-
Lou, H.1
Gao, L.2
Wei, X.3
Zhang, Z.4
Zheng, D.5
Zhang, D.6
Zhang, X.7
Li, Y.8
Zhang, Q.9
-
118
-
-
79952117065
-
Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line
-
[118] Zhang, Z., Zhang, X., Xue, W., Yangyang, Y., Xu, D., Zhao, Y., Lou, H., Effects of oridonin nanosuspension on cell proliferation and apoptosis of human prostatic carcinoma PC-3 cell line. Int. J. Nanomed. 5 (2010), 735–742.
-
(2010)
Int. J. Nanomed.
, vol.5
, pp. 735-742
-
-
Zhang, Z.1
Zhang, X.2
Xue, W.3
Yangyang, Y.4
Xu, D.5
Zhao, Y.6
Lou, H.7
-
119
-
-
84863040835
-
RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin
-
[119] Xu, J., Zhao, J.H., Liu, Y., Feng, N.P., Zhang, Y.T., RGD-modified poly(D,L-lactic acid) nanoparticles enhance tumor targeting of oridonin. Int. J. Nanomed. 7 (2012), 211–219.
-
(2012)
Int. J. Nanomed.
, vol.7
, pp. 211-219
-
-
Xu, J.1
Zhao, J.H.2
Liu, Y.3
Feng, N.P.4
Zhang, Y.T.5
-
120
-
-
84863036433
-
Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin
-
[120] Duan, C., Gao, J., Zhang, D., Jia, L., Liu, Y., Zheng, D., Liu, G., Tian, X., Wang, F., Zhang, Q., Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin. Biomacromolecules 12 (2011), 4335–4343.
-
(2011)
Biomacromolecules
, vol.12
, pp. 4335-4343
-
-
Duan, C.1
Gao, J.2
Zhang, D.3
Jia, L.4
Liu, Y.5
Zheng, D.6
Liu, G.7
Tian, X.8
Wang, F.9
Zhang, Q.10
-
121
-
-
41349120910
-
Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions
-
[121] Gao, L., Zhang, D., Chen, M., Duan, C., Dai, W., Jia, L., Zhao, W., Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355 (2008), 321–327.
-
(2008)
Int. J. Pharm.
, vol.355
, pp. 321-327
-
-
Gao, L.1
Zhang, D.2
Chen, M.3
Duan, C.4
Dai, W.5
Jia, L.6
Zhao, W.7
-
122
-
-
41349096647
-
Preparation and evaluation of self-microemulsifying drug delivery system of oridonin
-
[122] Zhang, P., Liu, Y., Feng, N., Xu, J., Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int. J. Pharm. 355 (2008), 269–276.
-
(2008)
Int. J. Pharm.
, vol.355
, pp. 269-276
-
-
Zhang, P.1
Liu, Y.2
Feng, N.3
Xu, J.4
-
123
-
-
57049152323
-
Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin
-
[123] Liu, Y., Zhang, P., Feng, N., Zhang, X., Wu, S., Zhao, J., Optimization and in situ intestinal absorption of self-microemulsifying drug delivery system of oridonin. Int. J. Pharm. 365 (2009), 136–142.
-
(2009)
Int. J. Pharm.
, vol.365
, pp. 136-142
-
-
Liu, Y.1
Zhang, P.2
Feng, N.3
Zhang, X.4
Wu, S.5
Zhao, J.6
-
124
-
-
84867055462
-
Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease
-
[124] Liby, K.T., Sporn, M.B., Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol. Rev. 64 (2012), 972–1003.
-
(2012)
Pharmacol. Rev.
, vol.64
, pp. 972-1003
-
-
Liby, K.T.1
Sporn, M.B.2
-
125
-
-
34247526984
-
Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer
-
[125] Liby, K.T., Yore, M.M., Sporn, M.B., Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer 7 (2007), 357–369.
-
(2007)
Nat. Rev. Cancer
, vol.7
, pp. 357-369
-
-
Liby, K.T.1
Yore, M.M.2
Sporn, M.B.3
-
126
-
-
84908400222
-
Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives
-
[126] Xu, S., Pei, L., Li, D., Yao, H., Cai, H., Yao, H., Wu, X., Xu, J., Synthesis and antimycobacterial evaluation of natural oridonin and its enmein-type derivatives. Fitoterapia 99 (2014), 300–306.
-
(2014)
Fitoterapia
, vol.99
, pp. 300-306
-
-
Xu, S.1
Pei, L.2
Li, D.3
Yao, H.4
Cai, H.5
Yao, H.6
Wu, X.7
Xu, J.8
-
127
-
-
84901793595
-
Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives
-
[127] Xu, S., Li, D., Pei, L., Yao, H., Wang, C., Cai, H., Yao, H., Wu, X., Xu, J., Design, synthesis and antimycobacterial activity evaluation of natural oridonin derivatives. Bioorg. Med. Chem. Lett. 24 (2014), 2811–2814.
-
(2014)
Bioorg. Med. Chem. Lett.
, vol.24
, pp. 2811-2814
-
-
Xu, S.1
Li, D.2
Pei, L.3
Yao, H.4
Wang, C.5
Cai, H.6
Yao, H.7
Wu, X.8
Xu, J.9
-
128
-
-
84976299831
-
Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis
-
[128] Bohanon, F.J., Wang, X., Graham, B.M., Ding, C., Ding, Y., Radhakrishnan, G.L., Rastellini, C., Zhou, J., Radhakrishnan, R.S., Enhanced effects of novel oridonin analog CYD0682 for hepatic fibrosis. J. Surg. Res. 199 (2015), 441–449.
-
(2015)
J. Surg. Res.
, vol.199
, pp. 441-449
-
-
Bohanon, F.J.1
Wang, X.2
Graham, B.M.3
Ding, C.4
Ding, Y.5
Radhakrishnan, G.L.6
Rastellini, C.7
Zhou, J.8
Radhakrishnan, R.S.9
-
129
-
-
84946482175
-
Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells
-
[129] Bohanon, F.J., Wang, X., Graham, B.M., Prasai, A., Vasudevan, S.J., Ding, C., Ding, Y., Radhakrishnan, G.L., Rastellini, C., Zhou, J., Radhakrishnan, R.S., Enhanced anti-fibrogenic effects of novel oridonin derivative CYD0692 in hepatic stellate cells. Mol. Cell Biochem. 410 (2015), 293–300.
-
(2015)
Mol. Cell Biochem.
, vol.410
, pp. 293-300
-
-
Bohanon, F.J.1
Wang, X.2
Graham, B.M.3
Prasai, A.4
Vasudevan, S.J.5
Ding, C.6
Ding, Y.7
Radhakrishnan, G.L.8
Rastellini, C.9
Zhou, J.10
Radhakrishnan, R.S.11
-
130
-
-
84941190738
-
Molecular insight in the multifunctional effects of oridonin
-
[130] Owona, B.A., Schluesener, H.J., Molecular insight in the multifunctional effects of oridonin. Drugs R. D. 15 (2015), 233–244.
-
(2015)
Drugs R. D.
, vol.15
, pp. 233-244
-
-
Owona, B.A.1
Schluesener, H.J.2
|